title: Rodent models for the preclinical evaluation of drugs suitable for pharmacological intervention in aging.
abstract: BACKGROUND
  There is a growing scientific and public interest in the development of new antiaging drugs for the purposes of extending mean and/or maximum life span, maintaining normal physiological function, and alleviating the onset and severity of age-associated diseases. This review looks at the current screening approaches used to evaluate the efficacy of such compounds, with a particular focus on those that extend life span.
  
  
  METHODS
  This article reviews the current preclinical approaches for assessing longevity therapy including the assessment of antiaging drugs (aging reversal) and geroprotectors (drugs that prevent premature aging and/or slowdown or postpone aging). This article also discusses the methods and the importance in evaluating the anticarcinogenic potential and safety of antitumor drugs.
  
  
  CONCLUSIONS
  Based on more than 30 years of experience in the field, the authors believe that the standard testing protocols for antiaging drugs should include the simultaneous evaluation of the drug's safety, as well as its antitumor and anticarcinogenic activity potential. The authors also believe that the principles of international programs for the expert critical evaluation of pharmacological interventions should be created to improve the range of antiaging interventions available for human studies.
authors.affiliation: N.N. Petrov Research Institute of Oncology, Department of Carcinogenesis and Oncogerontology, St. Petersburg, Russia. aging@mail.ru
authors.forename: Vladimir N
authors.initials: VN
authors.lastname: Anisimov
authors.forename: Mark A
authors.initials: MA
authors.lastname: Zabezhinski
authors.forename: Irina G
authors.initials: IG
authors.lastname: Popovich
authors.forename: Gennady B
authors.initials: GB
authors.lastname: Pliss
authors.forename: Vladimir G
authors.initials: VG
authors.lastname: Bespalov
authors.forename: Valeri A
authors.initials: VA
authors.lastname: Alexandrov
authors.forename: Alexander N
authors.initials: AN
authors.lastname: Stukov
authors.forename: Ivan V
authors.initials: IV
authors.lastname: Anikin
authors.forename: Irina N
authors.initials: IN
authors.lastname: Alimova
authors.forename: Peter А
authors.initials: PА
authors.lastname: Egormin
authors.forename: Andrey V
authors.initials: AV
authors.lastname: Panchenko
authors.forename: Tatiana S
authors.initials: TS
authors.lastname: Piskunova
authors.forename: Anna V
authors.initials: AV
authors.lastname: Semenchenko
authors.forename: Margarita L
authors.initials: ML
authors.lastname: Tyndyk
authors.forename: Maria N
authors.initials: MN
authors.lastname: Yurova
mesh_terms: D000375:Aging / Q000187:drug effects* / Q000502:physiology; D000818:Animals; D016588:Anticarcinogenic Agents / Q000009:adverse effects / Q000494:pharmacology; D000970:Antineoplastic Agents / Q000009:adverse effects / Q000494:pharmacology; D004195:Disease Models, Animal; D015195:Drug Design; D004353:Drug Evaluation, Preclinical / Q000379:methods*; D006801:Humans; D008136:Longevity; D051379:Mice; D051381:Rats
chemical_list: D016588:Anticarcinogenic Agents; D000970:Antineoplastic Agents